By Pierre Bertrand

 

Sanofi shares fell in early Wednesday trading after the company discontinued its global clinical development program for breast-cancer drug amcenestrant.

At 0733 GMT, shares of the French pharmaceutical company traded 4.1% lower to EUR83.01.

An independent data-monitoring committee found that amcenestrant, which targets a type of advanced or metastatic breast cancer, didn't satisfy the requirements for continued study and recommended stopping the trial, Sanofi said.

The decision to shelve the treatment program was based on the interim review of its Phase 3 Ameera-5 trial. All other trials involving the drug, including its AMEERA-6 early-stage breast cancer trial, will be discontinued, Sanofi said.

The end of amcenestrant's development program comes after the drug's Phase 2 clinical trial failed in March.

 

Write to Pierre Bertrand at pierre.bertrand@wsj.com

 

(END) Dow Jones Newswires

August 17, 2022 04:00 ET (08:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Sanofi Charts.